In this episode of CardiaCast, world-renowned hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will review changes occurring in the field of HCM and explore best practice recommendations from the newly issued guideline, 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

This podcast is part of the 2024 Update to the AHA/ACC HCM Guidelines: Expert Interpretation for Application to Practice grant initiative presented by ACCF and Med-IQ. Educational grant support is provided by Bristol Myers Squibb. Click here for more education on HCM: www.acc.org/learnHCM

Related References:

1. Maron BA, Wang RS, Carnethon MR, et al. What causes hypertrophic cardiomyopathy? Am J Cardiol 2022;179:74-82.
2. Rosenzveig A, Garg N, Rao SJ, et al. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy. Expert Opin Pharmacother 2023;24:1349-60.
3. Liao YW, Redfern J, Somauroo JD, Cooper RM. Hypertrophic cardiomyopathy and exercise restrictions: time to let the shackles off? Br J Cardiol 2020;27:11.
4. Lampert R, Ackerman MJ, Marino BS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol 2023;8:595-605.
5. Conway J, Min S, Villa C, et al. The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy. Circulation 2023;147:718-27.
6. Carrick RT, Maron MS, Adler A, et al. Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF Score. Circ Arrhythm Electrophysiol 2021;14:e009796.
7. Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020;142:217-29.
8. Norrish G, Qu C, Field E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678-86.
9. Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol 2023;8:968-77.
10. Owens A, Sherrid M, Rader F, et al. Cumulative long-term efficacy and safety of mavacamten treatment in nonobstructive hypertrophic cardiomyopathy: updated interim analysis from the MAVERICK cohort of the MAVA-long-term extension (LTE) study up to 120 weeks. J Card Fail 2024;30(suppl 1):S2-S3.